| Assessment Status | Rapid Review Complete |
| HTA ID | 26036b |
| Drug | Cemiplimab |
| Brand | Libtayo® |
| Indication | Cemiplimab (Libtayo®) in combination with platinum-based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 1% of tumour cells) with no EGFR, ALK or ROS1 aberrations, and who either have locally advanced NSCLC and who are not candidates for definitive chemoradiation, or who have metastatic NSCLC. |
| Assessment Process | |
| Rapid review commissioned | 10/07/2026 |
| Rapid review completed | 17/08/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that cemiplimab in combination with platinum-based chemotherapy, for the indication under assessment, not be considered for reimbursement at the submitted price*. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here